Vitae Pharmaceuticals (VTAE) : Traders are bullish on Vitae Pharmaceuticals (VTAE) as it has outperformed the S&P 500 by a wide margin of 171.36% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 158.87%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 160.25% in the last 1 week, and is up 165.86% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 136% and the 50-Day Moving Average is 120.18%.The 200 Day SMA reached 114.92% Vitae Pharmaceuticals, Inc. is up 108.04% in the last 3-month period. Year-to-Date the stock performance stands at 15.75%.
Vitae Pharmaceuticals (VTAE) : The most positive equity analysts on Vitae Pharmaceuticals (VTAE) expects the shares to touch $21, whereas, the least positive believes that the stock will trade at $10 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $17.4 with an expected fluctuation of $4.83 from the mean.
Company shares have received an average consensus rating of Hold for the current week Vitae Pharmaceuticals (NASDAQ:VTAE): The stock opened at $20.85 and touched an intraday high of $20.95 on Friday. During the day, the stock corrected to an intraday low of $20.84, however, the bulls stepped in and pushed the price higher to close in the green at $20.95 with a gain of 0.53% for the day. The total traded volume for the day was 4,129,196. The stock had closed at $20.95 in the previous trading session.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.